8-K: 60 Degrees Pharma Updates on Clinical Timelines, Babesiosis Strategy

60 Degrees Pharmaceuticals, Inc. provided an investor presentation detailing updated clinical development timelines and its regulatory strategy for Tafenoquine, including its potential for chronic babesiosis treatment.

Summary

• Presented an investor update via webinar hosted by RedChip Companies, Inc. on January 8, 2026.
• The presentation included updated clinical development timelines and regulatory strategy for Tafenoquine (ARAKODA).
• Market capitalization is $2.1 million as of 2025.
• Sales of ARAKODA for Chronic Babesiosis are increasing, with US Pharmacy Deliveries rising from 550 in Q3 2023 to 1,505 in Q3 2025 (16 ct box equivalents).
• Net Product Revenues increased from $51,000 in Q3 2023 to $438,000 in Q3 2025.
• Experienced a temporary stock-out in Q2 2025, leading to a decrease in pharmacy deliveries.
• Reported a net loss of $100,000 in Q3 2025, primarily due to an anticipated write-off of expiring, short-dated inventory.
• Future sales of ARAKODA could significantly increase, with chronic babesiosis potentially exceeding malaria prevention sales, assuming FDA approval.
• ARAKODA offers a lower pill burden for malaria prevention (16 pills for a one-month trip vs. 53 for standard of care).
• The company is pursuing FDA approval and broader acceptance for Tafenoquine in treating babesiosis, with an earliest feasible submission date of Q4 2026.
• Three clinical trials are underway or planned to confirm efficacy against babesiosis and investigate persistent infection.

Sentiment

Score: 4

Explanation: The company shows increasing sales for a key product and promising clinical development for a new indication. However, the explicit 'substantial doubt as to our ability to continue on a going-concern basis' and recent net loss due to inventory write-off significantly weigh down the sentiment, indicating high financial risk despite operational progress.

Positives

• Increasing sales of ARAKODA for Chronic Babesiosis, with US Pharmacy Deliveries growing from 550 in Q3 2023 to 1,505 in Q3 2025.
• Significant increase in Net Product Revenues from $51,000 in Q3 2023 to $438,000 in Q3 2025.
• ARAKODA demonstrates a lower pill burden for malaria prevention (16 pills for a one-month trip compared to 53 for standard of care).
• Tafenoquine showed an 80% cure rate in 5 immunosuppressed babesiosis patients in a study.
• Potential for future ARAKODA sales to increase by orders of magnitude, with chronic babesiosis sales potentially surpassing malaria prevention.
• Gross margins are described as 'looking good' despite a recent net loss.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Experienced a temporary stock-out in Q2 2025, which impacted pharmacy deliveries.
• Reported a net loss of $100,000 in Q3 2025, attributed to an anticipated write-off of expiring, short-dated inventory.
• Low brand recognition for ARAKODA in the malaria prevention market.
• Generic alternatives have lower out-of-pocket costs, posing a competitive challenge.
• G6PD testing requirement is a potential barrier for some travelers using ARAKODA.
• The company has no manufacturing capacity, which could lead to lengthy and costly delays.

Risks

• Substantial doubt as to the company's ability to continue on a going-concern basis.
• Uncertainty regarding eligibility for Australian government research and development tax rebates.
• Risk of not successfully developing, obtaining FDA approval for, and commercializing non-malaria prevention indications for Tafenoquine (ARAKODA or other regimen) or Celgosivir/Australian Chestbut extracts in a timely manner.
• Inability to guarantee successful clinical trials.
• Lack of manufacturing capacity, which poses the risk of lengthy and costly delays in bringing products to market.
• Actual results and financial conditions could differ materially from forward-looking statements due to various important factors beyond the company's control.

Future Outlook

The company anticipates significant growth in ARAKODA sales, particularly for chronic babesiosis, potentially surpassing malaria prevention sales, contingent on FDA approval. The earliest feasible submission date for FDA approval for babesiosis is Q4 2026. Three clinical trials are underway to confirm efficacy and understand persistent infection in babesiosis, with key milestones expected throughout 2026, including diagnostic confirmation, additional sales outputs, and interim analyses of hospital studies.

Management Comments

• "Malaria is an awful disease that needs to be attacked full-force when a diagnosis is made." (Paraphrased from a patient quote, presented by the company)
• "Chronic Babesiosis is seen in the vast majority of my chronically ill patients with Lyme disease. Present regimens with Mepron and Zithromax or clindamycin and quinine are insufficient in many cases to clear the infection. We need more studies on drugs like tafenoquine, for Chronic Babesiosis, as this persistent parasite is one of the reasons my patients do not get better." (Dr. Richard Horowitz, quoted by the company)
• "Every week I see kids and adults who have manifestations of Chronic Babesiosis, often presenting as severe neuropsychiatric symptoms." (Dr. Shannon Delaney, quoted by the company)

Industry Context

The company operates in the infectious disease space, addressing the growing concern of malaria in travelers, often due to non-compliance with medication, and the emerging challenge of babesiosis, a tick-borne and blood-transmissible parasitic infection. The increasing recognition of chronic babesiosis, particularly in immunocompromised individuals or those with dysregulated immune systems, highlights a significant unmet medical need. The company's focus on developing Tafenoquine for babesiosis aligns with the need for more effective treatments beyond conventional therapies that may not eliminate parasite reservoirs.

Comparison to Industry Standards

• ARAKODA offers a significantly lower pill burden for malaria prevention (16 pills for a one-month trip) compared to the standard of care (Atovaquone/proguanil/primaquine, which requires 53 pills).
• Current regimens for chronic babesiosis, such as Mepron and Zithromax or clindamycin and quinine, are considered insufficient in many cases by prescribing physicians like Dr. Richard Horowitz, indicating a need for new treatments like tafenoquine.
• Tafenoquine's mechanism of action against Babesia and Malaria parasites is similar, suggesting a broad-spectrum antiparasitic potential.

Stakeholder Impact

• Shareholders: Face significant risk due to the 'going concern' doubt, but also potential upside from successful clinical trials and market expansion for ARAKODA.
• Patients: Potential benefit from new treatments for malaria and chronic babesiosis, especially given ARAKODA's lower pill burden and efficacy in babesiosis.
• Healthcare Providers: Could gain a new treatment option for challenging conditions like chronic babesiosis.
• Employees: Uncertainty due to the company's financial viability (going concern).

Next Steps

• Achieve diagnostic confirmation of chronic babesiosis (Q1/Q2 2026).
• Generate additional sales outputs from the ARAKODA commercial program (Q1/Q2 2026).
• Achieve additional cures in the Expanded Access Study (Q3 2026).
• Reach minimum enrollment for interim analysis in the Hospital Study (Q3 2026).
• Conduct Hospital Study Interim Analyses (Q4 2026).
• Disclose final regulatory strategy for babesiosis (Q4 2026).
• Submit for FDA approval for babesiosis (earliest feasible Q4 2026).
• Continue outcomes from research pilot studies.
• Pursue new product development collaborations.
• Provide market updates and participate in trade & scientific conferences.

Key Dates

Recommendation

Despite some positive operational developments like increasing ARAKODA sales and promising clinical trial progress for babesiosis, the explicit disclosure of 'substantial doubt as to our ability to continue on a going-concern basis' is a critical red flag. This fundamental financial instability, coupled with a recent net loss from inventory write-offs and lack of manufacturing capacity, presents an extremely high-risk profile. While future potential exists, the immediate and severe financial viability concerns make the stock a 'sell' for risk-averse investors and warrant extreme caution for all others until these foundational issues are resolved.

Keywords

60 Degrees Pharmaceuticals, ARAKODA, Tafenoquine, Babesiosis, Malaria Prevention, Clinical Trials, FDA Approval, Pharmaceuticals, Infectious Disease, Drug Development, SEC Filing, Investor Presentation